Clinical Trial Update: Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating XPO-1 inhibitors in combination with CAR-T cells for relapsed/refractory B-cell non-Hodgkin's lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T cells
• XPO-1 inhibitors

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Status: UNKNOWN